In this review, we assess the current role of single-photon emission computed tomography
(SPECT) and positron emission tomography (PET) in the imaging of skeletal metastatic …

Bone scintigraphy augmented with radiographs or cross-sectional imaging, such as
computed tomography (CT) or magnetic resonance imaging (MRI), has remained the …

Somatostatin receptor scintigraphy is an accurate imaging modality for the diagnosis of
neuroendocrine tumor. Because detection of distant metastases has a major impact on …

BACKGROUND Positron emission tomography (PET) is a nuclear medicine technique that
only recently has been widely used in clinical oncology. PET, as a metabolic imaging …

The skeleton is the third most common site for metastasis overall, after the lungs and liver.
Accurate diagnosis of osseous metastasis is critical for initial staging, treatment planning …

Bone metastases are common, especially in more prevalent malignancies such as breast
and prostate cancer. They cause significant morbidity and draw on health-care resources …

The current standard of practice for the detection of osseous metastatic disease is the
conventional bone scan of the entire body using technetium-99m methylene diphosphonate …

There is growing evidence that molecular imaging of bone metastases with positron-
emission tomography (PET) can improve diagnosis and treatment response assessment …

18 F-fluorocholine is a specific promising agent for imaging tumor cell proliferation,
particularly in prostate cancer, using PET/CT. It is a beneficial tool in the early detection of …

Assessing bone metastases is often beyond the scope of plain-film radiography, and nuclear
imaging in particular with bone scintigraphy has proved the mainstay for detection of bony …